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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To investigate the effects of oral nutritional supplements on venous leg ulcer healing in adults.
B A C K G R O U N D
Description of the condition
Venous leg ulcers are chronic wounds on the lower leg caused by
poor venous return from the feet to the heart (due to varicose
or blocked veins). They usually affect older people, with some
estimates that up to 1% of people will be affected by a leg ulcer at
some point in their life in industrialised countries (Graham 2003;
O’Meara 2014) with higher prevalence in females aged over 70
years (Iglesias 2004). The average cost of treating a venous ulcer
with dressings varied between EURO1332 and EURO2585 in
Sweden and between EURO814 to EURO1994 in the United
Kingdom (UK) (Ragnarson Tennvall 2005). The cost-of-illness of
leg ulcer treatment in Hamburg revealed mean annual total costs
of EURO9060/patient/year and associated high costs of leg ulcers
for health insurances, patients and society (Augustin 2012). The
prevalence in less industrialised countries is not fully described
as yet, but it is likely that venous ulcers may also affect people
across settings. Leg ulcers usually take months to heal completely
and often recur after healing. Some people are affected by venous
ulcers for many years and the leakage of wound fluid from the
ulcer, smell, itch and pain can reduce quality of life and self image,
and occasionally lead to low mood and depression (Briggs 2007;
Briggs 2012).
Compression heals themajority of venous leg ulcers (Nelson 2014)
as this tackles the underlying cause of the ulceration with other
therapies such as nutritional support being adjunctive and the
focus of this study. Venous ulcers are thought to heal quickest
when the blood supply from the leg is supported by compression
bandages or stockings (Nelson 2014) when the wound is covered
in a dressing that keeps it moist (not wet and not dry), and when
the person’s ability to repair wounds is supported, for example by
making sure that the skin has sufficient resources supplied by the
arteries, such as oxygen and nutrients available to repair the ulcer.
Compression bandages or stockings are applied from toe to knee
and these can interfere with washing and bathing, and are often
bulky and unsightly. Scheduling treatment can affect quality of
life as it usually includes very frequent dressings (so people need
to arrange their life around visits to the nurse or doctor’s office, or
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home visits).
The body’s ability to heal can be optimised by treatment of arte-
rial disease to improve arterial blood supply; this aims to ensure
that the tissue receives adequate oxygen and nutrients and waste
products are removed. Surgery can improve venous insufficiency
(Wittens 2015) and help prevent ulcers coming back with ambu-
latory compression but is not always possible due to the type of
vein problem, or some people not wanting or feeling too unwell
for surgery. As well as ensuring that the body’s vascular supply can
deliver oxygen and nutrients to the body, other potential limits
to tissue repair, such as reduced oxygen (which may be caused by
respiratory disease) and nutrient levels, may be considered.
The use of oral nutritional supplements containing a range of
nutrients may be an effective way of increasing nutrient levels of
people with leg ulcers and consequently improving the rate of leg
ulcer healing. People with leg ulcers are at risk of malnutrition
because, as well as losing nutrients from ulcers due to leakage of
fluid from tissues, they are often older and their dietary intake may
be poor. A high prevalence of protein-energy (’calories’) malnutri-
tion in older adults has been reported (Green 2005; Kaiser 2010).
This type of malnutrition has been associated with a wide range of
factors, including poor appetite and self reported health (van der
Pols-Vijlbrief 2014). In addition to this, intake of micronutrients
(vitamins and minerals) from habitual diet can be poor (ter Borg
2015). People over 50 years of age with chronic leg ulcers have
been shown to have low levels of some micronutrients, namely
vitamins and minerals, such as vitamins A and E and zinc (Rojas
1999). It is important that treatment of malnutrition is considered
because it has been suggested that it affects the healing prognosis
of people with leg ulcers (Wissing 2012).
Programmes that promote changes in eating and drinking be-
haviour can improve dietary intake, but behavioural change is not
always maintained (Fjeldsoe 2011). Oral nutritional supplement
use is a health behaviour that may be adopted by people with ve-
nous leg ulcers (Miller 2014). Currently, people in the primary
care setting in the UK may be prescribed oral nutritional supple-
ments containing protein and energy if they are considered to have
or be at risk of protein-energy malnutrition (NICE 2012). Pa-
tients are usually screened for risk of protein-energy malnutrition
by nurses using a screening tool such as the British Association
for Parenteral and Enteral Nutrition (BAPEN) Nutritional Care
Tool (BAPEN 2016) . Use of screening tools are recommended
as best practice (NICE 2012) and are generally designed to detect
protein-energy malnutrition rather thanmicronutrient deficiency.
Therefore, those people of normal weight who consume a poor
quality diet may not meet the criteria for protein and energy-con-
taining oral nutritional supplement prescription.
People with leg ulcersmay be prescribedmultivitamin andmineral
supplements if they are considered to be at risk of micronutrient
deficiency (Johnston 2007). The use of oral nutritional supple-
ments in those not with, or not at risk of malnutrition may be
ineffective or detrimental (Johnston 2007). A previous Cochrane
review considered oral zinc supplementation and concluded that
there was insufficient evidence to determine whether zinc helped
the healing of arterial and venous leg ulcers (Wilkinson 2014).
However, the review was based on a small number of small studies
which were mostly of poor quality (Wilkinson 2014).
Description of the intervention
We will review any interventions comprising oral products con-
taining macronutrients (protein, fat and carbohydrate) and mi-
cronutrients (vitamins and minerals) alone or in combination,
with the intention of supplementing the oral diet. The term
’oral nutritional supplement’ is defined as a product for use in
oral nutrition support with the aim of increasing nutritional
intake (NICE 2006). Typically it describes a product contain-
ing a mix of macronutrients and micronutrients (Stratton 2010;
Webster-Gandy 2012). In this review the term ’oral nutritional
supplement’ will include any products containing one or more nu-
trients for oral consumption and will include micronutrient sup-
plements. Micronutrients include minerals and vitamins that are
needed by the human body in small quantities (Webster-Gandy
2012).Minerals include zinc, iodine, iron, cobalt, chromium, cop-
per, manganese, fluoride, sodium, selenium and molybdenum.
Vitamins include vitamins A, C, D, E and K, as well as the B-
complex vitamins. The frequency with which oral nutritional sup-
plements are taken depends on the form that they take and is
tailored to the individual (Webster-Gandy 2012). Micronutrient
supplements are generally taken orally once daily in small quanti-
ties whilst supplements containing macronutrients are taken sev-
eral times a day depending on need. We will only review nutri-
tional supplements taken orally to supplement the diet as this is
the normal route for providing nutritional supplementation in the
primary care setting.
The British National Formulary (BNF) outlines types of oral nu-
tritional supplements that can be prescribed in Sections A2 (food
supplements) and Chapter 9 (vitamins and minerals) and this will
inform our exclusion and exclusion criteria (BNF 2016). We are
excluding in our definition of oral nutritional supplements all
products given with the intention of exerting a pharmaceutical/
pharmacokinetic effect, for example St. John’s wort. Some of these
may be licensed as food supplements or defined as nutritional
products in other ways in some countries. In addition, there may
not be the same way of classifying products in all jurisdictions,
however, we will not include them in the review. We will exclude
medicinal herbs, for example ginger, garlic, lavender, thyme, dan-
delion, peppermint and chamomile.
How the intervention might work
For the purpose of this review the potential links between chronic
wound healing of venous leg ulcers and nutrients are outlined be-
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low. The phases of wound healing rely on sufficient nutrients to
progress and when nutrients are unavailable the normal wound
healing process will be compromised (Brown 2010). Nutrients
form the cell structure (Wild 2010) and enable the cell to grow,
repair and divide. Therefore, it is logical to suggest that nutrient
provision should improve wound healing where nutrients are lack-
ing and nutrients are provided to replenish stores. A person’s nu-
trient intake may be less than is required because of poor dietary
intake, increased loss from the body or increased use due to disease
processes.
How a nutritional supplement might improve wound healing will
depend on a number of factors:
1. A deficiency of a nutrient essential to wound healing will limit
wound healing even if there is an abundance of other nutrients.
The classic example of this is vitaminC,where a deficiencywill pre-
vent the normal rate of collagen production (Jacob 2002). There is
little evidence to suggest that providing nutrients in excess of that
required will increase the rate of wound healing (Thomas 1997).
Providing an abundance of nutrients other than the one or ones
that are deficient is also unlikely to promote wound healing.
2. A recent review has suggested that there is a need for protein
supplementation as an intervention to encourage wound healing
and tissue repair (Cawood 2012). However, the issue of whether
provision of protein in excess of an individual’s daily requirement
promotes healing needs investigation.
3. It has been suggested that some nutrients have a specific role
to play in wound healing. An example of this is the amino acid
arginine (Arnold 2006), which is thought to have a role in cell
growth.
4. Transport of nutrients to the site of healing could be influenced
by the provision of nutrients that can improve tissue perfusion,
for example by increasing blood oxygen capacity and hydration.
5. The impact of nutritional support on wound healing is likely
to differ between acute and chronic wounds (Stechmiller 2010).
In conclusion, “optimal wound healing requires adequate nutri-
tion” (Stechmiller 2010 p61) and poor nutritional intake may de-
lay healing and impair wound strength.
Why it is important to do this review
Despite our knowledge that a varied diet containing an appro-
priate amount of calories, essential amino acids (proteins), vita-
mins and minerals is associated with health (by preventing long-
term health problems and supporting adequate tissue repair), we
are not sure whether people with venous ulcers (whom we sus-
pect often have at least one dietary deficiency) can improve their
chances of healing by taking a supplement as a food, liquid or
tablet. The Scottish Intercollegiate Guidelines Network (SIGN)
guideline for the management of chronic venous leg ulcers iden-
tified that there was no good quality evidence on the effectiveness
of nutrition interventions or nutritional supplementation in the
treatment of patients with venous leg ulcers (SIGN 2010). How-
ever, their summary of the evidence warrants updating. This will
inform practitioners’ decision-making on whether to offer advice
on dietary supplementation of micronutrients or macronutrients
and highlight future research needs.
O B J E C T I V E S
To investigate the effects of oral nutritional supplements on venous
leg ulcer healing in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs) including
cluster trials and cross-over trials (the latter only to the point of
cross-over).
Types of participants
Eligible participants will include people aged 18 years of age or
over, treated in any care setting, including in their own home,
with a venous leg ulcer however defined by the trialists. We will
include RCTs where the baseline nutritional status of participants
has been defined as adequate or inadequate; we will also include
RCTs where the baseline nutritional status has not been defined.
Types of interventions
We will include evaluations of oral nutritional supplements. This
will include oral nutritional supplements in any dose or form (e.g.
drink, dessert or tablet) from any product where contents such as
proteins and vitamins are stated.Wewill include RCTs comparing
standard clinical practice (e.g. dressings and compression) plus
nutritional supplement with standard clinical practice alone or
with placebo.Wewill also include RCTs comparing different types
of nutritional supplements added to standard clinical practice.
We will exclude trials where the only comparison is between stan-
dard diet and any of the following:
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• medicinal herbs (e.g. ginger, garlic, lavender, thyme,
dandelion, peppermint, chamomile);
• herbal therapies (e.g. St John’s wort, cranberry, soy
isoflavones, garlic, black cohosh, ginkgo biloba etc);
• homeopathic extracts of substances derived from botanical,
animal or mineral sources in micro doses intended to assist the
body’s natural mechanisms for protecting and healing itself;
• zinc supplements.
Types of outcome measures
Primary outcomes
Trialistsmeasure and reportwoundhealing inmany differentways,
including: time to complete wound healing, proportion of wounds
healed during follow-up and rates of change of wound size.
For this review we will include trials that report one or more of
the following.
• Time to complete healing of the reference venous ulcer.
• Time to complete healing of all ulcers (where there is more
than one ulcer).
• Number of venous ulcers completely healed during trial
follow-up (frequency of complete healing).
• Change (and rate of change) in venous ulcer area during
trial follow-up period.
Secondary outcomes
• Treatment costs.
• Cost-effectiveness.
• Acceptability for the patient, such as taste, gastric upset,
where recorded from a tool or by narrative.
• Adverse events.
• Adherence to the indicated use and dosage for the
supplement.
• Health-related quality of life, as measured by a validated
tool, such as SF-36 or EQ5D and/or disease-specific quality of
life instruments (Palfreyman 2010) designed for use with venous
ulcer patients, such as the Charing Cross Venous Ulcer
Questionnaire (CXVUQ), the Venous Leg Ulcer-Quality of Life
Questionnaire (VLU-QoL), the Loftus questionnaire, or the
Quality of Life Leg Ulcer Questionnaire (QoLFUQ).
Search methods for identification of studies
Electronic searches
Wewill search the following electronic databases for relevant stud-
ies:
• The Cochrane Wounds Specialised Register (to present);
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library) (latest issue);
• Ovid MEDLINE (1946 to present);
• Ovid MEDLINE (In-Process & Other Non-Indexed
Citations) (latest issue);
• Ovid EMBASE (1974 to present);
• Ovid AMED (1985 to present);
• EBSCO CINAHL Plus (1937 to present).
The draft search strategy for CENTRAL is presented in Appendix
1. We will adapt this strategy to search the other databases listed
above. We will combine the Ovid MEDLINE search with the
Cochrane Highly Sensitive Search Strategy for identifying ran-
domised trials in MEDLINE: sensitivity- and precision-maximis-
ing version (2008 revision) (Lefebvre 2011). We will combine the
EMBASE search with the Ovid EMBASE randomised trials filter
terms developed by the UK Cochrane Centre (Lefebvre 2011).
We will combine the CINAHL search with the randomised trials
filter terms developed by the Scottish Intercollegiate Guidelines
Network (SIGN 2015). We will not restrict studies with respect
to language, date of publication or study setting.
We will also search the following clinical trials registries for ongo-
ing and unpublished studies:
• ClinicalTrials.gov (http://www.clinicaltrials.gov/)
• WHO International Clinical Trials Registry (ICTRP) (
http://apps.who.int/trialsearch/Default.aspx)
• ISRCTN registry (http://www.isrctn.com/)
Searching other resources
We will search the bibliographies of all retrieved and relevant pub-
lications identified by the database searches for further studies. We
will identify and contact nutrition supplement companies, as well
as experts/authors in this field who are familiar with the literature,
to enquire about unpublished or ongoing studies.
We will also search websites and search engines such as Open
Grey (www.opengrey.eu), Zetoc (http://zetoc.mimas.ac.uk/) and
Google Scholar (http://scholar.google.com) to identify grey liter-
ature reports and conference proceedings.
Data collection and analysis
Two review authors will independently perform study selection,
data extraction and ’Risk of bias’ assessment. We will undertake
meta-analysis where feasible and appropriate.
Selection of studies
We will assess the titles and abstracts of publications identified as
a result of the search against the inclusion criteria for relevance.
Two review authors will independently do this and a third review
author will be available for consultation where differences arise
between the initial two review authors.
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We will obtain full copies of publications identified as potentially
relevant. We will obtain publications identified through reference
lists if the title is considered relevant. We will appraise publica-
tions meeting the inclusion criteria. Two review authors will in-
dependently assess full-text publications for inclusion, with dis-
agreements resolved by discussion with a third review author.
Data extraction and management
Two review authors will independently extract data, recording rel-
evant items using the latest version of the Review Manager soft-
ware (RevMan 2014). We will include duplicate studies found in
the multiple databases or reported in different publications only
once, ensuring that all relevant data are extracted. We will discuss
any disagreement within the review team.
We will extract the following data when possible on those trial
arms that are relevant to the review:
• Trial identifier (first author, year of publication).
• Country of origin.
• Trial design (e.g. parallel, cluster).
• Unit of randomisation and analysis.
• Patient selection criteria.
• Baseline information (e.g. ulcer size and duration,
nutritional status of patient).
• Number of participants randomly assigned to each trial
arm.
• Details of treatment regimen received by each group,
including details of the oral nutritional supplement(s).
• Details of any co-interventions provided (e.g. compression
therapy).
• Care setting.
• Duration of treatment.
• Primary and secondary outcome(s) (with definitions).
• Measurement tools used for assessing healing and other
outcomes.
• Outcome data for primary and secondary outcomes (by
group).
• Duration of follow-up.
• Number of withdrawals (by group).
• Publication status of study.
• Source of funding for trial.
When data aremissing from reports, wewill attempt to contact the
study authors to obtain this information. When a study with more
than two intervention arms is included, we will only extract data
from the intervention and control groups that meet the eligibility
criteria of the review.
Assessment of risk of bias in included studies
Two review authors will independently assess each included study
using The Cochrane Collaboration tool for assessing risk of bias
(Higgins 2011a). This tool addresses six specific domains, namely
sequence generation, allocation concealment, blinding, incom-
plete outcome data, selective outcome reporting and other issues
(e.g. extreme baseline imbalance) (see Appendix 2 for details of cri-
teria on which the judgement will be based). We will assess blind-
ing of outcome assessment and completeness of outcome data for
each outcome separately. We will complete a ’Risk of bias’ table
for each eligible study. We will discuss any disagreement amongst
all review authors to achieve a consensus.
Blinding of participants, care providers and outcome assessors will
be assessed by looking for explicit statements that these parties
were blind and not aware of treatment allocation. Low risk, high
risk or unclear will be recorded as detailed in Appendix 2.
RCTs will be classified as being at overall high risk of bias if they
are rated as having high risk in relation to at least any one of
three key domains (allocation concealment, blinding of outcome
assessors and completeness of outcome data - use of intention-to-
treat analysis). If none of the key domains are rated as high risk,
but one or more are rated as having an unclear risk of bias, the
RCT will be rated overall as having an unclear risk of bias. To
attain an overall low risk of bias, all three key domains will have
to be rated as low risk individually.
Risk of bias data will be extracted by one review author and inde-
pendently checked for accuracy by a second review author. Dis-
agreements about ratings will be resolved by discussion with the
third team member.
We will seek to identify selective outcome reporting by initially
seeking the protocol for each included RCT. Where available, the
protocol will be reviewed and compared to the published RCT
report to identify if all pre-specified (primary and secondary) out-
comes relevant to the review have been reported in the pre-spec-
ified way. Where the trial protocol is not available the published
report will be examined to: identify whether outcomes specified
in the methods section correspond to those reported in the re-
sults section and; determine whether all expected outcomes are
reported. We will note any pre-specified or expected outcomes
which have not been reported, also if any outcomes are reported
using measurements, analysis methods or subsets of the data (e.g.
subscales) that were not pre-specified or expected.
We will assess other sources of bias such as baseline imbalance of
prognostic variables (ulcer surface area, ulcer duration, patients’
nutritional status in cases of RCTs recruiting participants with
differing characteristics); we will also record source of funding
where recorded.
We will present our assessment of risk of bias using a ’Risk of
bias’ summary figure, which presents all of the judgements in a
cross-tabulation of study by entry. This display of internal validity
indicates the weight the reader may give the results of each study.
Measures of treatment effect
Where data are available from trial reports or trial authors we will
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calculate measures of treatment effect from individual RCTs using
the latest version of Review Manager (RevMan 2014).
For trials reporting the number of people/ulcers healed we will
summarise effects using the risk ratio (RR) and 95% CI. This is
in preference to the odds ratio (OR), as at event rates greater than
30% the OR (if interpreted as RR) can give an inflated impression
of the effect size (Deeks 2002).
For trials reporting continuous outcome measures such as rate of
reduction in area (expressed as absolute or relative changes in area),
or costs of care, we will summarise effects using mean difference
(MD) with 95% CI. We do not plan to dichotomise continuous
data or transform data into arbitrary categories, and we will there-
fore retain the maximum amount of information reported in the
primary studies.
For studies reporting time to healing we will present the results
as a hazard ratio (HR) with associated 95% confidence interval
(CI) where available. If the time to healing data are presented
(incorrectly) as a continuous variable, then, where feasible, we plan
to estimate the effects using other reported outcomes, such as the
numbers of events, through the application of available statistical
methods (Tierney 2007).
Unit of analysis issues
Unit of analysis issues may arise when: multiple limbs or ulcers on
the same individual are studied in a trial and such highly correlated
data are regarded as independent; and/or if multiple assessments
of the same outcome are presented. We will record whether trials
presented outcomes in relation to a venous ulcer, limb or partici-
pant, or as multiple venous ulcers/limbs on the same participant.
For wound healing, unless otherwise stated, when the number of
wounds appears to equal the number of participants, we will treat
the participant as the unit of analysis.
When a cluster-randomised trial has been conducted and cor-
rectly analysed, effect estimates and their standard errors may be
meta-analysed using the generic inverse variance method in Re-
view Manager (RevMan 2014).
When outcomes from a cluster-randomised trial have been incor-
rectly analysed (i.e. at the individual rather than the cluster level),
we will approximate the correct analyses if possible, in accordance
with Chapter 16 of the Cochrane Handbook for Systematic Reviews
of Interventions, using the information as suggested in Higgins
2011b:
• Number of clusters (or groups) randomly assigned to each
intervention group; or the average (mean) size of each cluster.
• Outcome data ignoring the cluster design for the total
number of individuals (e.g. number or proportion of individuals
with events, means and standard deviations).
• Estimate of the intracluster (or intraclass) correlation
coefficient (ICC).
Dealing with missing data
It is common to have data missing from trial reports. Excluding
participants from the analysis post randomisation or ignoring par-
ticipants who are lost to follow-up compromises the randomisa-
tion and potentially introduces bias into the trial. If it is thought
that study authors might be able to provide some missing data, we
will contact them; however, it is likely that data will often be miss-
ing because of loss to follow-up. In individual studies, when data
on the proportion of venous ulcers healed are presented, we plan
to assume that randomly assigned participants not included in an
analysis had an unhealed venous ulcer at the end of the follow-up
period (i.e. they will be considered in the denominator but not in
the numerator). When a trial does not specify participant group
numbers before dropout, we will present only complete case data
and make that clear in our narrative. For time-to-healing analysis
using survival analysis methods, dropouts should be accounted for
as censored data. Hence all participants will be contributing to the
analysis. We acknowledge that such analysis assumes that drop-
outs are missing at random. We will present data for area change
of venous ulcer and for all secondary outcomes as a complete case
analysis.
Assessment of heterogeneity
We will consider clinical heterogeneity (i.e. the degree to which
RCTs vary in terms of participant, intervention and outcome char-
acteristics) and statistical heterogeneity. Inspection of the trials by
the authors will determine the likelihood of clinical heterogeneity.
We will assess statistical heterogeneity using the Chi² test (we will
consider a significance level of p-value less than 0.10 to indicate
statistically significant heterogeneity) in conjunction with the I²
statistic (Higgins 2003). I² examines the percentage of total varia-
tion across RCTs that is due to heterogeneity rather than to chance
(Higgins 2003). We will consider that I² values of 40% or less
indicate a low level of heterogeneity, and values of 75% or more
indicate very high heterogeneity (Higgins 2011c). We will apply
the following decision rules for pooling:
· low heterogeneity (I2 40% or less) - use fixed effect model;
· moderate heterogeneity (I2 above 40% but below 75%) - use
random effects model;
· high heterogeneity (I2 75% or more) - refrain from pooling and;
· any instance of clinical heterogeneity (regardless of I2 estimation)
- refrain from pooling.
Assessment of reporting biases
Reporting biases arise when dissemination of research findings is
influenced by the nature and direction of results. Publication bias
is one of a number of possible causes of ’small-study effects’, that
is, a tendency for estimates of the intervention effect to be more
beneficial in smaller RCTs. Funnel plots allow a visual assessment
of whether small-study effects may be present in a meta-analysis.
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A funnel plot is a simple scatter plot of the intervention effect
estimates from individual RCTs against some measure of the size
or precision of each trial (Sterne 2011). We plan to present funnel
plots for meta-analyses comprising 10 or more RCTs using the
latest version of Review Manager (RevMan 2014).
Data synthesis
Wewill combine details of included studies in a narrative review ac-
cording to the comparators. In terms of meta-analytical approach,
we will not perform a meta-analysis in the presence of clinical
heterogeneity but we will present the results graphically, without
pooling, to allow the reader to appreciate the effect sizes and het-
erogeneity in the trials. We will explore the sources of that hetero-
geneity, for example, by considering whether subgroups of trials
may differ, with an aim of identifying the causes of clinical het-
erogeneity. In the absence of clinical heterogeneity we will select
a meta-analysis method according to the decision rule described
above Assessment of heterogeneity.
For dichotomous outcomes, we will present the summary estimate
as a risk ratio (RR) with 95% CI. When continuous outcomes
are measured in the same way across studies, we plan to present
a pooled mean difference (MD) with 95% CI. We plan to pool
standardised mean difference (SMD) estimates when studies have
measured the same outcome using different methods. We will
present pooled data using forest plots. For time-to-event data, we
plan to plot (and, if appropriate, pool) estimates of HR and 95%
CIs as presented in the study reports using the generic inverse
variance method in the latest version of ReviewManager (RevMan
2014).Wewill obtain pooled estimates of treatment effect by using
the latest version of Review Manager (RevMan 2014).
Subgroup analysis and investigation of heterogeneity
When possible, we will perform a subgroup analysis informed by
type and/or dose of supplement to explore the influence on effect
sizes, and subgroup analysis on baseline nutritional status where
trials record participants of adequate nutritional status versus tri-
als recruiting those with sub-optimal nutritional status. Type of
supplement will include oral nutritional supplements in any form
(drink, dessert or tablet). When possible, we will assess whether
there are differences stated between the effect of types of oral nu-
tritional supplements on venous ulcer healing.
Sensitivity analysis
When possible, we will perform sensitivity analyses to explore the
influence of overall risk of bias classification on effect sizes. We
will assess this by removing RCTs with overall high or unclear risk
of bias from the meta-analysis. We will only include studies that
are assessed as having low risk of bias in all three key domains
(allocation concealment, blinding of outcome assessors and com-
pleteness of outcome data - use of intention-to-treat analysis).
’Summary of findings’ tables
We will present the main results of the review in ’Summary of
findings’ tables. These tables present key information concerning
the quality of the evidence, the magnitude of the effects of the
interventions examined and the sum of available data for the main
outcomes (Schünemann 2011a). The ’Summary of findings’ ta-
bles also include an overall grading of the evidence related to each
of the main outcomes using the GRADE (Grades of Recommen-
dation, Assessment, Development and Evaluation) approach. The
GRADE approach defines the quality of a body of evidence as the
extent to which one can be confident that an estimate of effect or
association is close to the true quantity of specific interest. The
quality of a body of evidence involves consideration of within-
trial risk of bias (methodological quality), directness of evidence,
heterogeneity, precision of effect estimates and risk of publication
bias (Schünemann 2011b).
We plan to present findings related to the primary outcomes in
the ’Summary of findings’ tables, namely the following.
• Time to complete healing of the reference venous ulcer.
• Time to complete healing of all ulcers (where there is more
than one ulcer).
• Number of venous ulcers completely healed during trial
follow-up (frequency of complete healing).
• Adverse effects.
Where findings are identified in relation to the secondary out-
comes, we will describe these prior to analysis within the ’Sum-
mary of findings’ tables.
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A P P E N D I C E S
Appendix 1. The Cochrane Central Register of Controlled Trials (CENTRAL) provisional search
strategy
#1 MeSH descriptor: [Dietary Supplements] explode all trees
#2 MeSH descriptor: [Micronutrients] explode all trees
#3 MeSH descriptor: [Dietary Proteins] explode all trees
#4 MeSH descriptor: [Dietary Carbohydrates] explode all trees
#5 MeSH descriptor: [Dietary Fats] explode all trees
#6 MeSH descriptor: [Energy Intake] explode all trees
#7 (diet* near/3 (supplement* or fortification or capsule* or tablet* or liquid*)):ti,ab,kw
#8 (nutrient* near/3 (supplement* or fortification or capsule* or tablet* or liquid*)):ti,ab,kw
#9 ((micronutrient* or micro-nutrient* or vitamin* or multivitamin* or mineral* or trace next element* or zinc or iodine or iron or
cobalt or chromium or copper or manganese or fluoride or sodium or selenium or molybdenum) near/3 (supplement* or fortification
or capsule* or tablet* or liquid*)):ti,ab,kw
#10 ((macronutrient* or macro-nutrient* or protein* or amino next acid* or carbohydrate* or calorie* or energ* or fat* or lipid*) near/
3 (supplement* or fortification or capsule* or tablet* or liquid*)):ti,ab,kw
#11 ((food or diet) near/3 (intake or fortif*)):ti,ab,kw
#12 {or #1-#11}
#13 MeSH descriptor: [Leg Ulcer] explode all trees
#14 ((varicose next ulcer*) or (venous next ulcer*) or (leg next ulcer*) or (stasis next ulcer*) or (crural next ulcer*) or “ulcus cruris” or
“ulcer cruris”):ti,ab,kw
#15 {or #13-#14}
#16 {and #12, #15} in Trials
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Appendix 2. Risk of bias criteria
1. Was the allocation sequence randomly generated?
Low risk of bias
The investigators describe a random component in the sequence generation process such as: referring to a random number table; using
a computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots.
High risk of bias
The investigators describe a non-random component in the sequence generation process. Usually, the description would involve some
systematic, non-random approach, for example: sequence generated by odd or even date of birth; sequence generated by some rule
based on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number.
Unclear
Insufficient information about the sequence generation process to permit judgement of low or high risk of bias.
2. Was the treatment allocation adequately concealed?
Low risk of bias
Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent
method, was used to conceal allocation: central allocation (including telephone, web-based and pharmacy-controlled randomisation);
sequentially-numbered drug containers of identical appearance; sequentially-numbered, opaque, sealed envelopes.
High risk of bias
Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation
based on: use of an open random allocation schedule (e.g. a list of random numbers); assignment envelopes without appropriate
safeguards (e.g. envelopes were unsealed, non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record
number; any other explicitly unconcealed procedure.
Unclear
Insufficient information to permit judgement of low or high risk of bias. This is usually the case if the method of concealment is not
described or not described in sufficient detail to allow a definite judgement, for example if the use of assignment envelopes is described,
but it remains unclear whether envelopes were sequentially numbered, opaque and sealed.
3. Blinding - was knowledge of the allocated interventions adequately prevented during the study?
Low risk of bias
Any one of the following:
• No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be influenced by
lack of blinding.
• Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of
others unlikely to introduce bias.
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High risk of bias
Any one of the following:
• No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding.
• Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias.
Unclear
Either of the following:
• Insufficient information to permit judgement of low or high risk of bias.
• The study did not address this outcome.
4. Were incomplete outcome data adequately addressed?
Low risk of bias
Any one of the following:
• No missing outcome data.
• Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing
bias).
• Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a
clinically relevant impact on the intervention effect estimate.
• For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing
outcomes not enough to have a clinically relevant impact on observed effect size.
• Missing data have been imputed using appropriate methods.
High risk of bias
Any one of the following:
• Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing
data across intervention groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce
clinically relevant bias in intervention effect estimate.
• For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing
outcomes enough to induce clinically relevant bias in observed effect size.
• ’As-treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation.
• Potentially inappropriate application of simple imputation.
Unclear
Either of the following:
• Insufficient reporting of attrition/exclusions to permit judgement of low or high risk of bias (e.g. number randomised not stated,
no reasons for missing data provided).
• The study did not address this outcome.
5. Are reports of the study free of suggestion of selective outcome reporting?
Low risk of bias
Either of the following:
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• The study protocol is available and all of the study’s pre-specified (primary and secondary) outcomes that are of interest in the
review have been reported in the pre-specified way.
• The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that
were pre-specified (convincing text of this nature may be uncommon).
High risk of bias
Any one of the following:
• Not all of the study’s pre-specified primary outcomes have been reported.
• One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that
were not pre-specified.
• One or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as
an unexpected adverse effect).
• One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis.
• The study report fails to include results for a key outcome that would be expected to have been reported for such a study.
Unclear
Insufficient information to permit judgement of low or high risk of bias. It is likely that the majority of studies will fall into this category.
6. Other sources of potential bias
Low risk of bias
The study appears to be free of other sources of bias.
High risk of bias
There is at least one important risk of bias. For example, the study:
• had a potential source of bias related to the specific study design used; or
• has been claimed to have been fraudulent; or
• had some other problem.
Unclear
There may be a risk of bias, but there is either:
• insufficient information to assess whether an important risk of bias exists; or
• insufficient rationale or evidence that an identified problem will introduce bias.
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